# Vincristine

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

**EMLc** ATC codes: L01CA02

| | |
|---|---|
| **Indication** | Lymphoid leukaemia, not elsewhere classified ICD11 code: 2B33.3 |
| **INN** | Vincristine |
| **Medicine type** | Chemical agent |
| **List type** | Complementary |
| **Formulations** | **Parenteral > General injections > IV:** 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate) |
| **EML status history** | First added in 2011 (TRS 965)<br>Changed in 2015 (TRS 994)<br>Changed in 2021 (TRS 1035) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Tags** | Cancer |
| **Wikipedia** | Vincristine |
| **DrugBank** | Vincristine |

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.